The approval was for 510K predict and "Substantially Equivalent" as the previous generation of wheezo already had FDA approval, hence the review took the usual 6 months.
- Forums
- ASX - By Stock
- RAP
- Ann: Change of Director's Interest Notice - Chris Ntoumenopoulos
Ann: Change of Director's Interest Notice - Chris Ntoumenopoulos, page-92
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)